Capsule Summary Slidesets

Share

Program Content

Activities

  • HERTHENA-Lung01 CNS Analysis
    HERTHENA-Lung01: Intracranial Results From a Phase II Trial of HER3-DXd in Previously Treated Patients With Advanced EGFR-Mutated NSCLC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 23, 2023

    View Activity
  • monarchE 5 yr update
    monarchE 5-Yr Outcomes: Adjuvant Abemaciclib Plus ET in Patients With High-Risk, Node-Positive HR+/HER2- EBC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 23, 2023

    View Activity
  • LIBRETTO-431
    LIBRETTO-431: Randomized Phase III Trial of First-line Selpercatinib vs Chemotherapy Plus Pembrolizumab in RET Fusion‒Positive NSCLC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 24, 2023

    View Activity
  • TROPiCS-03 ES-SCLC Cohort
    TROPiCS-03 Phase II Basket Trial: Sacituzumab Govitecan as Second-line Therapy for Extensive-Stage Small-Cell Lung Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 24, 2023

    View Activity
  • ALINA
    ALINA: Randomized Phase III Trial of Adjuvant Alectinib vs Chemotherapy in Patients With Stage IB-IIIA ALK-Positive NSCLC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 25, 2023

    View Activity
  • MATTERHORN
    MATTERHORN: Interim Results From a Phase III Trial of Durvalumab + FLOT in Resectable Gastric and Gastroesophageal Junction Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 25, 2023

    View Activity
  • Neoadjuvant Cemiplimab for CSCC
    1-Yr Follow-up of Phase II Study of Neoadjuvant Cemiplimab for Stage II-IV Cutaneous Squamous Cell Carcinoma
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 25, 2023

    View Activity
  • RELATIVITY-047 Biomarkers
    RELATIVITY-047: Biomarker Analysis of First-line Nivolumab + Relatlimab vs Nivolumab in Advanced Melanoma
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 25, 2023

    View Activity
  • LIBRETTO-531
    LIBRETTO-531: Phase III Trial of Selpercatinib vs Cabozantinib or Vandetanib in Patients With Advanced RET-Mutant Medullary Thyroid Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 25, 2023

    View Activity
  • DAD Trial
    Double Antibody–Drug Conjugate (DAD): Phase I Trial of Sacituzumab Govitecan + Enfortumab Vedotin in Metastatic Urothelial Carcinoma
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 26, 2023

    View Activity
  • CheckMate 77T
    CheckMate 77T: Phase III Trial of Neoadjuvant Nivolumab + Chemotherapy vs Placebo + Chemotherapy With Adjuvant Nivolumab or Placebo in Stage II-IIIB NSCLC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 26, 2023

    View Activity
  • NICHE-3
    NICHE-3: Phase II Trial of Neoadjuvant Nivolumab + Relatlimab for Locally Advanced dMMR Colon Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 26, 2023

    View Activity
  • EMBER Imlunestrant in BC
    EMBER: Phase Ia/b Study of Imlunestrant, a Next-Generation Oral SERD, in Advanced ER+/HER2- Breast Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 27, 2023

    View Activity
  • Alliance A021602/CABINET NETs
    Alliance A021602/CABINET: Phase III Trial Evaluating Cabozantinib vs Placebo for Advanced Neuroendocrine Tumors After Disease Progression on 1 or More Therapies
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 27, 2023

    View Activity
  • EV-302/KEYNOTE-A39
    EV-302/KEYNOTE-A39: Phase III Trial of Enfortumab Vedotin + Pembrolizumab vs Chemotherapy in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 30, 2023

    View Activity
  • CheckMate 901
    CheckMate 901 Phase III Trial: First-line Nivolumab + Gemcitabine/Cisplatin vs Gemcitabine/Cisplatin Alone for Unresectable/Metastatic Urothelial Carcinoma
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 30, 2023

    View Activity
  • TROPION-Breast01
    TROPION-Breast01: Phase III Trial of Datopotamab Deruxtecan vs Chemotherapy for Patients With Previously Treated HR+ HER2- Metastatic Breast Cancer
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 31, 2023

    View Activity
  • TROPION-Lung01
    Phase III TROPION-Lung01: Datopotamab Deruxtecan vs Docetaxel for Previously Treated Advanced or Metastatic NSCLC
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 31, 2023

    View Activity
  • DESTINY-Breast T-DXd Brain Mets
    Trastuzumab Deruxtecan for Brain Metastases in HER2-Positive Metastatic Breast Cancer: A Pooled Analysis of DESTINY-Breast01, 02, and 03 Trials
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: November 01, 2023

    View Activity
  • DESTINY-PanTumor01
    DESTINY-PanTumor01: Phase II Study of Trastuzumab Deruxtecan in Patients With HER2-Activating Mutations in Solid Tumors
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: November 01, 2023

    View Activity

Provided by

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Inc., Exelixis, Inc., Gilead Sciences, Inc., Lilly and Regeneron Pharmaceuticals, Inc.

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis, Inc.

Gilead Sciences, Inc.

Lilly

Regeneron Pharmaceuticals, Inc